Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Five Patent Applications Relate to RNAi

Premium
Title: Composition for Treatment or Prevention of Endometrial Cancer and Method of Preventing or Treating Endometrial Cancer Using the Composition
 
Number: 7,381,819
 
Filed: Aug. 22, 2005
 
Lead Inventor: Churl Ki Min, Ajou University
 
The invention, the patent’s abstract states, comprises “a composition for the treatment or prevention of an endometrial cancer including a nuclear acid molecule inducing RNA interference against human syndecan-1 gene expression and a pharmaceutically acceptable carrier, and a method of treating or preventing an endometrial cancer including administering the composition to an individual.”
 

 
Title: Modified siRNA Constructs for Detecting RISCs
 
Number: 20080124730
 
Filed: Oct. 10, 2007
 
Lead Inventor: Kai Qin Lao, Applera
 
The patent application, its abstract states, claims “novel methods, compositions, and kits for detecting siRNA-containing RISCs. In some embodiments, modified siRNA constructs are employed that contain an antisense strand and a sense strand, wherein the antisense strand comprises a 3' end, wherein the 3' end comprises a fluorophore, and wherein the sense strand comprises a 5' end, wherein the 5' end comprises a quencher. Following transfection, uptake of the antisense strand by RISC liberates the fluorescent signal, allowing for detection of siRNA-containing RISCs.”
 

 
Title: Simultaneous Silencing and Restoration of Gene Function
 
Number: 20080125384
 
Filed: Nov. 21, 2006
 
Inventor: Shuewi Yang
 
According to the patent application’s abstract, the invention comprises a “method and composition for simultaneously silencing an endogenously transcribed polynucleotide sequence in a cell using RNAi and replacing the function of the endogenous sequence with the function of an exogenous polynucleotide sequence.” The application also claims “methods of treatment based on the above method, and pharmaceutical composition comprising the vectors of the … invention,” as well as “methods for verifying that silencing or knock-down of a gene in a cell … due to siRNA interference,” the abstract adds.
 

 
Title: RNA Interference Agents for Therapeutic Use
 
Number: 20080125386
 
Filed: Jan. 26, 2007
 
Lead Inventor: Tariq Rana, University of Massachusetts (RXi Pharmaceuticals)
 
“The invention features chemically modified small interfering RNAs that are stable in vivo and retain the ability to form an A-form helix when in association with a target RNA,” the patent application’s abstract states. “The features siRNA are effective therapeutics, particularly for targeting SOD1.”
 

 
Title: Ribonucleic Acid Interference Molecules
 
Number: 20080125583
 
Filed: Feb. 10, 2006
 
Lead Inventor: Isidore Rigoutsos, International Business Machines
 
The patent application, its abstract states, claims “ribonucleic acid interference molecules.
 
“For example, in one aspect of the invention at least one nucleic acid molecule comprising at least one of one or more [specific] precursor sequences … and one or more [specific] mature sequences … is provided. One or more of the … precursor sequences and one or more mature sequences may be computationally predicted … using a pattern discovery method.”
The abstract notes that another aspect of the invention comprises “a method for regulating gene expression” using the aforementioned nucleic acid molecule.
 

 
Title: Process for Producing a Decaffeinated Coffee Plant by Genetic Recombination
 
Number: 20080127373
 
Filed: Jan. 4, 2005
 
Lead Inventor: Shinjiro Ogita, Nara Institute of Science and Technology
 
The invention, the patent application’s abstract states, involves producing a decaffeinated coffee plant by genetic recombination comprising a step for preparing an antisense sequence or an RNAi sequence of a gene coding for an enzyme related to the caffeine biosynthetic pathway and constructing an expression vector for transformation; a step for introducing the obtained expression vector into agrobacterium; a step for infecting a cell division-activated tissue piece of a coffee plant … a callus, or an adventitious embryo induced from a tissue piece of a coffee plant with the agrobacterium to transform the tissue piece, the callus, or the adventitious embryo; and a step for obtaining an transformed coffee plant from a transformed tissue piece, a transformed callus, or a transformed adventitious embryo so that a coffee plant with low caffeine content can be produced by suppressing expression of a gene coding for an enzyme related to the caffeine biosynthetic pathway by the antisense method or the RNAi method.”

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.